NeuroPace (NPCE) Shareholder's Equity Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.44% |
| Dec 31, 2025 | 137.50% |
| Sep 30, 2025 | 88.52% |
| Jun 30, 2025 | 96.64% |
| Mar 31, 2025 | 69.23% |
| Dec 31, 2024 | -61.20% |
| Sep 30, 2024 | -39.97% |
| Jun 30, 2024 | -53.43% |
| Mar 31, 2024 | -47.83% |
| Dec 31, 2023 | -40.61% |
| Sep 30, 2023 | -62.31% |
| Jun 30, 2023 | -59.88% |
| Mar 31, 2023 | -56.24% |
| Dec 31, 2022 | -52.69% |
| Sep 30, 2022 | -46.88% |
| Jun 30, 2022 | -40.34% |
| Mar 31, 2022 | 140.16% |
| Dec 31, 2021 | 149.72% |
| Sep 30, 2021 | 156.85% |
| Jun 30, 2021 | 161.45% |
| Mar 31, 2021 | -15.17% |